glp 1 sanofi GLP-1 medication and its types Europe GLP-1 Agonist Market -

The 28.7% figure for retatrutide comes from TRIUMPH-4, a Phase 3 trial of 445 adults living with obesity and knee osteoarthritis, reported by Lilly in a December 2025 press release

Its ability to increase feelings of fullness, reduce calorie intake, and delay the emptying of the stomach have all contributed to substantial weight loss in clinical trials

The initial product GLP-1 (137) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (736) amide and GLP-1 (737)

Zeng et al

The 6-day half-life is the technical reason for once-weekly dosing

Overall, 74 percent of people on the drug reported stomach issues like nausea and vomiting